(Q36632266)

15 August 2017

1 reference

title

Raloxifene and the prevention of breast cancer (English)

1 reference

15 August 2017

Therese B Bevers

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

16

1 reference

15 August 2017

page(s)

2301-2307

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Phase II Evaluation of Lyl56758 in Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.16.2301

10.1517/14656566.7.16.2301

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference